During the corresponding time, Adagene Inc recorded a revenue increase by 7332.76 % year on year, While revenue at the Adagene Inc 's corporate clients
Adagene Inc's Comment on Sales, Marketing and Customers
The company serves customers classified as CIIOs or operators handling critical data, particularly those engaged in activities related to national security that require cybersecurity review prior to agreements. Customers identified as posing risks such as disruption, vulnerability to attacks, or threats to national security protection may be denied access to the company's products or services. The company has not been subject to cybersecurity investigations by the Cyberspace Administration of China nor received regulatory objections concerning its Nasdaq listing. However, uncertainties remain regarding compliance with evolving laws and regulations, including potential requirements for pre-approval by the China Securities Regulatory Commission (CSRC) for overseas securities offerings or maintaining Nasdaq listing status. Additionally, industry-specific regulations, such as the PRC State Council's Regulations on the Administration of Human Genetic Resources effective May 2024, affect data collection and transfer, requiring approvals for international projects involving human genetic resources.
In a strategic move that signals the ongoing evolution of cancer therapeutics, Adagene Inc. has announced a licensing agreement with Third Arc Bio, Inc. to develop two masked CD3 T cell engagers utilizing Adagene’s proprietary SAFEbody technology. The agreement, unveiled on November 13, 2025, marks a significant milestone not just for the companies involved, but also for the broader field of immuno-oncology. Key Facts from the Agreement: 1. Collaboration Overview : Under this new partnership, Third Arc Bio will leverage Adagene s SAFEbody platform to create masked CD3 T cell engagers that target unique tumor-associated antigens. This innovative approach aims to enhance the efficacy and safety profile of c...
The treatment landscape for metastatic microsatellite-stable (MSS) colorectal cancer (CRC) has been evolving rapidly, with immunotherapy playing a significant role. In a recent study, Adagene presented interim results highlighting the potential of their novel therapy, masked anti-CTLA-4 SAFEbody ADG126 (muzastotug), in combination with pembrolizumab. This article aims to provide an analysis of the study s findings and their implications for the treatment of MSS CRC.Clinical Study Overview:The study evaluated the clinical efficacy of ADG126 in combination with pembrolizumab in MSS CRC patients. The first tranche of patients received a dosage of ADG126 at 10 mg/kg every three weeks (Q3W) as part of the dose e...
Adagene Inc’s Comment on Sales, Marketing and Customers
The company serves customers classified as CIIOs or operators handling critical data, particularly those engaged in activities related to national security that require cybersecurity review prior to agreements. Customers identified as posing risks such as disruption, vulnerability to attacks, or threats to national security protection may be denied access to the company's products or services. The company has not been subject to cybersecurity investigations by the Cyberspace Administration of China nor received regulatory objections concerning its Nasdaq listing. However, uncertainties remain regarding compliance with evolving laws and regulations, including potential requirements for pre-approval by the China Securities Regulatory Commission (CSRC) for overseas securities offerings or maintaining Nasdaq listing status. Additionally, industry-specific regulations, such as the PRC State Council's Regulations on the Administration of Human Genetic Resources effective May 2024, affect data collection and transfer, requiring approvals for international projects involving human genetic resources.
Sources:
Adagene Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Adagene Inc’s corporate clients.
For your research, we’ve provided 9 tables on Adagene Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
